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Abstract
Ferritin is the main intracellular protein of iron storage with a central role in the regulation of
iron metabolism and detoxification. Nucleotide insertions in the last exon of the ferritin light
chain cause a neurodegenerative disease known as Neuroferritinopathy, characterized by
iron deposition in the brain, particularly in the cerebellum, basal ganglia and motor cortex.
The disease progresses relentlessly, leading to dystonia, chorea, motor disability and neu-
ropsychiatry features. The characterization of a good animal model is required to compare
and contrast specific features with the human disease, in order to gain new insights on the
consequences of chronic iron overload on brain function and behavior. To this aim we stud-
ied an animal model expressing the pathogenic human FTL mutant 498InsTC under the
phosphoglycerate kinase (PGK) promoter. Transgenic (Tg) mice showed strong accumula-
tion of the mutated protein in the brain, which increased with age, and this was accompa-
nied by brain accumulation of ferritin/iron bodies, the main pathologic hallmark of human
neuroferritinopathy. Tg-mice were tested throughout development and aging at 2-, 8- and
18-months for motor coordination and balance (BeamWalking and Footprint tests). The Tg-
mice showed a significant decrease in motor coordination at 8 and 18 months of age, with a
shorter latency to fall and abnormal gait. Furthermore, one group of aged naïve subjects
was challenged with two herbicides (Paraquat and Maneb) known to cause oxidative dam-
age. The treatment led to a paradoxical increase in behavioral activation in the transgenic
mice, suggestive of altered functioning of the dopaminergic system. Overall, data indicate
that mice carrying the pathogenic FTL498InsTC mutation show motor deficits with a devel-
opmental profile suggestive of a progressive pathology, as in the human disease. These
mice could be a powerful tool to study the neurodegenerative mechanisms leading to the
disease and help developing specific therapeutic targets.
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Introduction
Iron is essential for cell viability, including electron transport in the respiratory chain, catabo-
lism of neurotransmitters and neuronal development and myelination in the central nervous
system [1–4]. Brain iron levels are not detectable at birth and start accumulating later during
development. The causes of iron accumulation during aging are still unclear but could be relat-
ed to dysfunction of blood brain barrier [5, 6] and to apoptosis and cellular damage [7]. Iron
homeostasis must be finely regulated because iron is essential but also potentially toxic. In fact
when in excess, iron can catalyze the formation of highly reactive free radicals via Fenton−like
reactions. High iron deposition occurs in most neurodegenerative disorders including Alzhei-
mer’s and Parkinson’s diseases, amyothropic lateral sclerosis, prion disease and a pool of genet-
ic disorders collectively identified as Neurodegeneration with Brain Iron Accumulation
(NBIA) [8, 9]. In these pathologies, local alterations of iron levels and/or of proteins involved
in iron metabolism (particularly ferritins) have been reported, but it is unclear whether this is a
causative factor or whether it represents a consequence of the degenerative processes.
Ferritins are ubiquitous iron storage molecules that play a central role in the regulation of
iron metabolism and detoxification. Cytosolic ferritins are 24-mer heteropolymers composed
of tissue-specific proportions of H- and L-chains, while mitochondrial ferritins are homopoly-
mers [10]. The ferritins bind and incorporate iron in their large cavity by complex reactions
that involve Fe(II) oxidation catalyzed by the ferroxidase center in the H subunit, followed by
iron hydrolysis and mineralization facilitated by acidic residues of L-chains [11]. In this man-
ner ferritins control Fe(II) availability and reduce radical oxygen species (ROS) production.
DNA variations in the H−ferritin gene are very rare and its deletion in knockout mice is lethal
at the embryonic stage [12]. In contrast, DNA variations in L-ferritin gene (FTL) are more
common, and nucleotide insertions that modify the C-terminal region cause movement disor-
ders named neuroferritinopathies, that are inherited with dominant transmission. Neuroferri-
tinopathy was discovered in 2001 in a large pedigree in England, and now there are more than
seventy cases found in Europe, America and Asia. It is a late-onset movement disorder charac-
terized by neurodegeneration and abnormal brain iron accumulation (NBIA).
Nine pathogenic mutations of the FTL gene have been reported so far. One is a missense
mutation in the third exon, whose pathogenicity is questioned [13]. All the other ones are one-
or multiple-nucleotide insertions in the fourth exon that determine a frameshift and alterations
of the C-terminus region involved in the four-fold symmetry channel. The largest study inves-
tigated subjects with the original 460InsA mutation, the clinical phenotypes was characterized
in 40 English patients [14, 15]. The 498InsTC genotype was reported in 7 patients with symp-
toms similar to those of the 460InsA type [16, 17]. The genotype 458dupA was described in 4
French patients [18]. The mutation 469–484dup16nt was found in a single subject in Japan
[19] and in one in Italy [20]. The 442dup4bp genotype was described in 7 Japanese patients
[21], and the 442InsC found in two cases [22]. The last two mutations are a duplication of a
thymine in position 468 described in a single France patient and the mutation
468_483dup16bp found in a Japanese family [23, 24]. The genotypes showed a complete pene-
tration, with heterogeneity of clinical manifestations that were difficult to attribute to the dif-
ferent genotypes [25]. The clinical onset of neuroferritinopathy is around 40 years. The
majority of patients presented focal onset chorea or focal dystonia and reported a family histo-
ry of movement disorders [14]. Serum ferritin level is generally low.
Magnetic resonance imaging (MRI) studies show cerebral and cerebellar atrophy and ab-
normal signals in the basal ganglia [26, 27]. The disease progresses relentlessly and becomes
generalized in 5–10 years, leading to aphonia, dysphagia and motor disability, with cognitive
dysfunction in a late feature [9, 14]. In these patients, both neurons and glial cells show
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accumulation of intranuclear and intracytoplasmic inclusion bodies containing wild type and
mutated ferritin light chain, ferritin heavy chain and iron. These aggregates are more abundant
in the caudate nucleus, putamen and globus pallidus, but also present throughout the gray and
white matter of the brain. Signs of neurodegeneration − including axonal swelling, cysts forma-
tion and increased immunoreactivity for neurofilaments, ubiquitin and tau protein − are most
evident in the areas where inclusion bodies are formed [17, 22, 27]. Basal ganglia are involved
in motor control and are particularly rich in iron in adult age [28]. Excessive cellular iron, asso-
ciated with increased oxidative stress and the generation of reactive oxygen species (ROS), has
damaging effects on many cellular processes [10, 29, 30] and can interfere with both the direct
and the indirect pathway of movement contributing to the pathophysiological alterations in
neurodegenerative disease, such as Parkinson and Neuroferritinopathy [31]. In particular,
striatal-thalamo-cortical dysfunction induced by nigral dopaminergic degeneration has been
demonstrated to be responsible for the occurrence of rigidity and bradykinesia [32, 33], while
cerebellar-thalamic-cortical dysfunction may be involved in the occurrence of tremor in Par-
kinson’s disease [33, 34].
The effect of the pathogenic mutations is to disrupt important amino acid interactions for
the correct folding around the hydrophobic channel whose integrity is necessary for protein
functionality [35]. The biological effects of the mutations have been studied in cellular models,
showing that they alter iron homeostasis with an increase of free iron and ferritins accompa-
nied by higher sensitivity to hydrogen peroxide and oxidative damage [36]. This is consistent
with a dominant negative effect of the mutations on ferritin functionality [35]. Animal models
would be very important to characterize the disorder. A transgenic mouse model expressing a
human cDNA carrying the FTL498InsTC mutation driven by the mouse prion protein
(MoPrP) Xho promoter [37], was generated and characterized by Vidal and colleagues [38].
These mice showed alteration in the intracellular localization of ferritin already at the earliest
ages examined (4 months), followed by an age-dependent progressive intracellular accumula-
tion [38]. These authors described a progressive neurological phenotype with a significant de-
crease in motor performance, and a shorter lifespan [39]. We studied a new transgenic mouse
model, similar to that described by Vidal, expressing the same pathogenic mutant of human
ferritin-L chain but under the phosphoglycerate kinase (PGK) promoter, that has recently been
characterized [40]. As it is similar to the one described by Vidal [38] it was named Tg.
Materials and Methods
Animals
A transgenic FVB-mouse model expressing the pathogenic human FTL mutant 498InsTC
under the PGK promoter has been generated by pronuclear microinjection [40]. The FVB/N
strain is recommended for transgenic-mice generation [41], but it shows a poor performance
in several behavioral tests [42]. For this reason, the Tg mice were backcrossed for 7 generations
in the C57BL/6J background.
Mice were group-housed in the same room provided by air conditioning (temperature 21 ±
1°C, relative humidity 60 ± 10%), in transparent Plexiglas cages (29cm × 12cm × 14cm), under
a reversed 12/12 hr light/dark cycle (lights off 08:00–20:00). Pellet food (standard diet Altro-
min-R, Rieper, Italy) and tap water were continuously available. Animal handling and experi-
mental procedures were performed in accordance with the EC guidelines (EC Council
Directive 86/609 1987) and with the Italian legislation on animal experimentation (Decreto L.
vo 116/92), and the project was approved Italian Ministry of Health.
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Experimental Procedures
Quantitative qRT-PCR
Mice (3 male and 3 female 12-month-old Tg-mice) were anesthetized with Avertine (23 μl/gr
mouse; Sigma) and perfused with a physiological saline solution containing 2% heparin; brain
samples were then removed, dissected and immediately frozen. RNA was recovered from the dif-
ferent areas of the mouse brain with TRI Reagent (Sigma Aldrich) according to the manufactur-
er’s instructions. Reverse transcription was performed using 2μg RNA, oligo-dT, and Improm
Reverse Transcriptase (Promega) in 20μl. Samples of 2μl were used for quantitative reverse-tran-
scription polymerase chain reaction (qRT-PCR) assay, using iTaq Universal SYBR Green
(BioRad) according to the manufacturer’s instructions. Extracted levels were quantified with
qRT-PCR in a relationship to Hprt1 mRNA. Primers used to amplify humFTL were 5’-CCTA-
GATGAGGAAGTGAAGCTT-3’ and 5’- AGAGATACTCGCCCAGCCC-3’, and for HPRT1
were 5’CTGGTTAAGCAGTACAGCCCCAA-3’ and 5’-CAGGAGGTCCTTTTCACCAGC-3’.
Histochemistry and immunohistochemistry
Analyses were performed at different ages: 6, 12 and 18 months-old (groups of at least 3 Tg
and 3 WT-mice per age). Mice were anesthetized with Avertine (23 μl/gr mouse; Sigma) and
perfused transcardially with paraformaldehyde 4% (Biooptica, Milan, Italy); the organs were
removed and stored at -80°C (for histochemical analysis) or embedded in paraffin (for immu-
nohistochemical analysis).
For histochemistry, brains were cut serially in 40 μm-thick sections using a cryostat. To
show the presence of iron deposits, sections were stained with Prussian blue followed by 3, 3’-
diaminobenzidine (DAB) for enhanced Perl’s reaction and counterstained with nuclear fast red
0.01% (Merck). Quantitative analysis of iron deposits (brown deposits) was performed in ran-
domly selected cortical areas. Digitally fixed images (standardized arbitrary area) for each sec-
tion (5 sections/animal) was evaluated using an optical microscope (Olympus BX50, Olympus,
Hamburg, Germany) at a final magnification of 20X. The percentage of brown staining/field
was calculated using a digital color video camera equipped with an image analysis program
(Image Pro-Plus, Milan, Italy). The fields were randomly selected by two investigators unaware
of the animal group assignment. Statistical analysis was performed using Anova One-Way
Test, corrected by Bonferroni with P<0.05 considered as significant.
For immunohistochemistry, brains were cut serially in 7 μm-thick sections using a micro-
tome. Human FTL expression was detected using a mouse monoclonal antibody named LF03
(1:100 for 2 hr at 21°C), previously described [43]. The reaction product was visualized using
hydrogen peroxide and DAB (5mg/10ml PBS) as chromogen. Negative control for immunohis-
tochemical reaction was performed by omitting the primary antibody. Quantitative analysis of
LF03 immunopositivity was performed evaluating the percentage of brown staining in stan-
dardized area using an optical microscope (Olympus, Germany) equipped with an image ana-
lyzer (Image Pro-Plus, Milan, Italy).
Iron-chelator treatment
To reduce the iron load, groups of 3 mice, 12-month-old, were treated for 3 weeks with the oral
iron-chelator Deferiprone. It was dissolved in sweetened drinking water to 1mg/ml, and we con-
trolled that water consumption, with and without the chelator, was the same, about 7ml per day.
Neurotoxicant drugs treatment
The FVB/N strain is recommended for transgenic generation (Taketo, Schroeder et al. 1991),
but it shows a poor performance in several behavioral tests (Mineur and Crusio 2002).
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Therefore we thought to use these aged mice to verify differences in response to environmental
neurotoxicant exposures, which are hypothesized to increase the risk of developing neurode-
generative disorders (McCormack, Thiruchelvam et al. 2002; Thiruchelvam, McCormack et al.
2003). To test this hypothesis, we administered the herbicide Paraquat (PQ) and the fungicide
Maneb (MB) to 21-month-old WT and Tg-mice. The treatment with PQ+MB have been previ-
ously shown to cause damage of the nigrostriatal system and to lead to neuronal death (McCor-
mack, Thiruchelvam et al. 2002; Murray-Kolb, Welch et al. 2003; Thiruchelvam, McCormack
et al. 2003). Transgenic-mice (n = 5) and wild-type (n = 5) littermates were given a single IP in-
jection of the herbicide Paraquat (10mg/Kg dissolved in saline) and one of the fungicide
Maneb (30mg/Kg dissolved in vegetable oil). The mice were tested in the Open Field and Beam
Walking tests 24 h after the treatments.
Behavioral Tests
Transgenic C57-mice and their wild-type littermates were studied at different ages with differ-
ent behavioral tests. Mice were divided in three groups of different age: a) young mice, 2-
month-old (n = 7 male and 7 female WT; n = 8 male and 8 female Tg); b) adult mice, 8-
month-old (n = 18 male and 12 female WT; n = 15 male and 13 female Tg); c) aged mice, 18-
month-old (n = 6 male and 5 female WT; n = 5 male and 5 female Tg). Motor coordination
and balance were assessed using BeamWalking and Footprint test. Each behavioral test was
video recorded and scored with specific software (Observer, Noldus).
Open Field Test
Spontaneous locomotor activity was measured using a standard Open Field test [44]. Mice
were individually placed in the center of a cubic arena (freshly cleaned open field box 44cm ×
44cm × 44cm) made of grey Plexiglas and allowed to freely explore for 20 min with a novel ob-
ject in the center of the arena during the last 5 minutes (a 50 ml glass beaker); The open-field
box was ideally divided into 25 squares. When data were analyzed, each session was subdivided
in 4 time blocks (tb) and the latency, frequency and duration of locomotion (the number of
lines crossed or squared entered with four paws), exploratory activity (sniffing and rearing),
risk assessment (stretched-attend posture—SAP), self-directed behaviors (self-grooming) and
object exploration (sniffing and touching) were scored [44–46]. Behaviors were defined as
follows:
- crossing: crossing the square limits with all paws;
- sniffing: self-explanatory;
- rearing: standing on the hind paws;
- stretched-attend posture: exploratory posture in which the body is stretched forward and
then retracted to the original position without any forward locomotion;
- self-grooming, rubbing the body with paws or mouth and rubbing the head with paws.
BeamWalking Test
Motor coordination and balance were evaluated by the ability of mice to traverse two narrow
beams of different diameter to reach an enclosed safety platform [47]. Beams were horizontal
and 50 cm above the table. Mice were trained to traverse a beam of 2 cm in diameter and then
of 1 cm in diameter. Latency to traverse each beam and latency to fall were recorded.
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Hind-paw Footprint Test
This test was used to compare the gait of mutant mice with that of wild type control mice [48,
49]. To obtain footprints, the hind- and forefeet of the mice were coated with black and green
nontoxic paints, respectively. The animals were then allowed to walk along a 50-cm-long, 10-
cm-wide runway (with 10-cm-high walls) into an enclosed box and a sheet of white paper was
placed on the floor of the runway. To characterize the walking pattern of each mouse we mea-
sured the average distance between each stride (stride length, SL) and the distance between left
and right hind footprints (hind-base width, HB) and left and right front footprints (fore-base
width, FB), respectively (all measured in millimeters).
Statistical Analysis
Data were analyzed using parametric analysis of variance (ANOVA) with “genotype” (wild
type and Tg) and “gender” (male and female) as between-subjects factors and “trial” and
“time” as within-subject repeated measures, when appropriate (BeamWalking, Rotarod, Open
Field). Post hoc comparisons were performed using the Tukey’s test. Statistical analysis was
performed using Statview II (Abacus Concepts, CA, USA). Data are expressed as mean + SEM.
A significance level of 0.05 was chosen.
Results
Immunoistochemical and biochemical characterization of the Tg-mouse
The initial analyses performed on the different areas of the brain of Tg-mice showed that the
expression of the transgene transcript was higher in the hippocampus compared with cortex,
cerebellum and midbrain (Fig. 1).
Fig 1. Evaluation of exogenous human FTLmRNA in the indicated areas of the brain of 8 month-old
Tg-mice. Solid circles for males and the empty ones for females. The horizontal lines are the means. Data
obtained by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The transcript of the
transgene was higher in males than females, and higher in the hippocampus> cortex> cerebellum
>midbrain.
doi:10.1371/journal.pone.0118990.g001
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Immunohistochemical analysis confirmed the high expression of the transgene and showed
that its concentration increased with aging (Fig. 2A), in parallel with the endogenous ferritins
(data not shown). The new transgenic mouse model confirmed the presence of ferritin/iron
bodies in most tissues, principally in the brain: the main hallmark of the ferritinopathy patients
and of the reported ferritinopathy mouse model [38, 40]. The inclusions became detectable
with DAB-enhanced Perl’s reaction in 6-month-old mice, then the number and size of the
granules increased with age. To have a quantitative evaluation of the iron bodies, we measured
the percentage of brown staining area in various fields (Fig. 2B).
Because the deposits in the brain are Perl’s positive and are similar to hemosiderin, and he-
mosiderin can be solubilized in conditions of systemic iron deficiency, the treatment with
Deferiprone, an oral iron-chelator, could reduce iron load in transgenic mice. Three weeks-
Deferiprone-treatment reduced not only serum iron but also the number and sizes of the iron
positive granules (Fig. 2C).
Effect of neurotoxicant drugs on the Tg-mouse in FVB background
The Tg-mice in the FVB background did not show remarkable phenotypes and behaved simi-
larly to the wt mice in behavioral tests. Thus, they were treated with herbicides, Paraquat and
Maneb to induce neurodegenaration. The treatment resulted in an unexpected increase in loco-
motor and exploratory activities in the Tg-mice compared to wild-type littermates, as indicated
by crossing (interaction between genotype and treatment F(1, 8) = 6.670; 3.998; P = 0.0325;
0.0806, respectively for frequency and duration) (Fig. 3A, 3B), sniffing (interaction between ge-
notype and treatment F(1, 8) = 5.012, P = 0.05) (Fig. 3C) and rearing (interaction between ge-
notype and treatment F(1, 8) = 11.310, P = 0.0099) (Fig. 3D).
Motor coordination and balance of the Tg-mouse in C57BL/6
background
BeamWalking Test. Tg adult mice showed a lower latency to fall from the beams compared
to wild-type (main effect of genotype F(1, 53) = 5.797, P = 0.0196) (Fig. 4), female mice show-
ing an even shorter latency (interaction among trial, genotype and gender F(1, 53) = 5.701,
P = 0.0206). No difference emerged in the performance between transgenic and wild-type mice
at young (no main effect of genotype F(1, 26) = 0.401, P = 0.5319) and old (no main effect of
genotype F(1, 17) = 2.305, P = 0.1473) age. At 8-month one wt male mouse found to be outlier
and was therefore discarded from the analysis (Grubbs’ test performed by GraphPad Software).
At 18 months, a main effect of gender also appeared, female mice were more able to stay on the
beam without falling, compared to males, although this effect did not interact with genotype
(main effect of gender F(1, 17) = 6.005, P = 0.0254).
Hind-paw Footprint Test. In order to confirm the motor phenotype of the mutants as a
progressive movement disorder, adult and old mice were tested in the Footprint test to assess
gait. In the 18-month-old group Tg male mice displayed an abnormal pattern in the fore-base
width (interaction between genotype and gender F(1, 13) = 8.451, P = 0.0122) (Fig. 5A). No sig-
nificant differences were found in this age group between wt and Tg-mice when measuring
hind-base width HB (no main effect of genotype F(1, 13) = 0.379, P = 0.5490) (Fig. 5B) or stride
length SL (no main effect of genotype F(1, 13) = 3.164, P = 0.0986) (Fig. 5C). No difference was
found in the adult groups (no main effect of genotype F(1, 13) = 0.039; 3.039; 2.488; P =
0.8469; 0.1005; 0.1343 respectively for stride length, fore-base width and hind-base width mea-
surements). Unfortunately, we could not use all the recorded footprints for the statistical analy-
sis since, as it often happens, some mice retrace their own steps, making their paths unclear
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Fig 2. Ferritin and iron accumulation in the brain of Tg-mice. (A) Paraffin-embedded brain sections (40 μm thick) of Tg and control mice were stained with
a specific antibody for human L-ferritin chain. (B) Slices stained with DAB-enhanced Perl’s reaction showed a strong accumulation of ferritin/iron bodies in
Tg-mouse brains. The quantitative evaluation of the percentage of brown staining in various fields showed the increase of the number and size of the
granules with aging. At the optical microscope these granules seemed to be present mostly in neurons, and in the center of the cells in a nuclear/paranuclear
position. (C) Mice were treated for 3 weeks with oral iron chelator Deferiprone (DFR) 1 mg/ml in drinking water ad libitum to reduce iron burden. The treatment
reduced inclusion bodies in the brain both in number and in size.
doi:10.1371/journal.pone.0118990.g002
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and hardly interpretable. Indeed, only 4–5 footprints in each group were sufficiently clear to
be analyzed.
Discussion
Neuroferritinopathy is caused by 9 types of mutation in the FTL gene, the most common is the
460InsA, with more than 40 patients described [25]. The other mutations were found in isolat-
ed cases and could not be followed in detail [14]. Animal models of the disorder are helpful to
characterize the disease and to try therapeutic approaches. To this aim we studied an animal
model expressing the pathogenic human FTL mutant 498InsTC under the phosphoglycerate
kinase (PGK) promoter [40]. Notably, this mutant expresses a transgene similar to the one de-
scribed by Vidal’s laboratory [38]. Both animal models were characterized by the formation of
iron bodies in the brain and other tissues, which increased in number and size with age. These
bodies, and their time dependent accumulation in the brain, represent the hallmark of the dis-
order, a finding that confirms that these are proper models of neuroferritinopathy.
Fig 3. Assessment of spontaneous locomotor activity 24 h following administration of PQ+MB in old
mice (21 month-old). After treatment Tg-mice showed increased locomotor (A, B) and exploratory activities
(C, D), compared to wild type subjects of the same age. Results are presented as mean + S.E.M.
* P< 0.05.
doi:10.1371/journal.pone.0118990.g003
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Initial studies were performed in FVB background, the mouse strain normally used for
transgene production. Even after ageing up to 2 years, no locomotor differences could be de-
tected from the comparison with control littermates, possibly because the FVB background is
known not to be adequate for behavioral studies. Several risk factors, such as environmental
neurotoxicant exposures, have been hypothesized to increase the risk of developing neurode-
generative disorders, possibly including neuroferritinopathy. To test this hypothesis, Tg and
control aged mice were treated with the herbicide Paraquat and the fungicide Maneb. These
compounds have been previously shown to cause damage of the nigrostriatal system and to
lead to neuronal death [50–52]. Although in most studies these herbicides are administered for
a long period of time, because of their toxicity, we administered them only via an acute admin-
istration. Interestingly, while no major motor deficits emerged, 24 hours following the first
treatment, the Tg-mice showed increased locomotor and exploratory activities compared to
control subjects. These initial data suggest that adding up the brain iron accumulation with ad-
ditional oxidative stress caused by PQ+MB treatment, in aged mice might result in a paradoxi-
cal behavioral activation. Prolonged elevation of ferritin levels within dopaminergic midbrain
neurons results in their progressive age-related neurodegeneration [53]. This is initially mani-
fested as a striatal axonopathy accompanied by loss in locomotor function and is followed by a
significant loss in striatal dopamine content and subsequent dopaminergic cell loss in the sub-
stantia nigra [53]. Oxidative stress, such as that caused by exposure to herbicides, might inter-
act with the pathological consequences of iron accumulation leading to a peculiar motor
phenotype such as that previously described. Indeed, oxidative stress has been shown to alter
normal dopaminergic neurotransmission [54] and to increase dopaminergic activity [55]
Fig 4. Assessment of motor function using the BeamWalking test. Tg adult mice (8 month-old) showed
a lower latency to fall from the beams compared to wild-type. Results are presented as mean + S.E.M.
* P< 0.05.
doi:10.1371/journal.pone.0118990.g004
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inducing relevant adaptive responses of dopaminergic receptors in specific brain regions [56].
It is also demonstrated that stress manipulations induced the alteration in motor activity of ex-
perimental animals, and dopaminergic pathways are crucial to neural substrates for the control
of spontaneous locomotor activity [57]. It is thus possible to hypothesize that accumulation of
ferritin/iron might lead to a paradoxical increase in dopaminergic activity, suggesting a “posi-
tive” feedback on the nigrostriatal system. It would be important to assess, in future studies the
long-term effects of exposure to toxicants and their interaction with the pathological pheno-
type characterizing NBIA.
The C57BL/6 strain is better suited for behavioral studies, thus we backcrossed the original
FVB mouse strain for 7 generations in C57BL/6J. We thought important to assess behavioral
Fig 5. Assessment of gait using Footprint test. Tg old male mice (18 month-old) showed a significantly reduced fore-base width compared to controls (A).
Results are presented as mean + S.E.M. * P< 0.05.
doi:10.1371/journal.pone.0118990.g005
Animal Models of Neuroferritinopathies
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abnormalities well before the occurrence of neurodegeneration since they might represent pre-
cocious hallmarks of the pathology, before the clinical phenotype is observed. Thus, wild-type
and transgenic animals were studied at different ages to assess motor function in a battery of
tests commonly used to this purpose, such as BeamWalking and Footprint tests. Different sub-
jects were used at different ages to avoid carry−over effects of previous testing. Results for
motor coordination using the BeamWalking test indicate that an effect of the genotype
emerges at adult age (8 months) with an inability of the Tg-mice to traverse a beam compared
to wild-type, while no difference was found at younger or older age. This might be explained by
the fact that, while in young subjects the phenotype is not yet evident, this might be masked in
the old group by their tendency to be immobile, thus not traversing the pole at all.
In order to characterize more quantitatively differences in gait, the Footprint test was used
and an abnormal gait pattern was found in the old male Tg-mice. The impairment in this spe-
cific measure suggests a profound motor deficit caused by an inability of the animal to success-
fully extend forepaws. Abnormal gait has been referred to impaired cerebellar motor or
peripheral neurological function. Although we did not find significant differences in the stride
length, it is important to consider that the number of subjects was necessarily low as in this test
some subjects had to be discarded because they often walk backward on their own footsteps
thus making it very difficult to assess the walking path.
Overall, data confirm that transgenic mice display a number of motor abnormalities remi-
niscent of those occurring in neuroferritinopathy, including locomotor abnormalities [14].
However the ones we observed in our Tg-mice were less severe than those described by the
group of Vidal [38]. We were able to identify the time windows associated to disease phenotype
manifestation. In particular, we found a significant decrease in motor performance at adult age
(8 months). Motor deficits progressively worsened with age, 18 months-old Tg-mice showing
gait abnormalities. As for gender differences, interestingly we found that at adulthood (8
months) female Tg-mice revealed a poorer motor performance than males, while in the old age
this was totally reverted. These data are in line with a large body of evidence indicating gender
differences in the rate of aging, with females overall showing healthier phenotypes as they be-
come older [58]. This effect might have partially masked the pathological phenotype in the
aged subjects and indicates that attention must be paid to gender x genotype effects in these pa-
thologies. Numerous biological mechanisms could underlay these effects, as an example, sex
hormones such as estrogen might influence brain aging attenuating the age-related decline in
female subjects [59].
Neuroferritinopathies are key examples of pathologies in which brain iron dysregulation is
tightly associated with neurodegeneration. Since iron accumulation is also observed in Parkin-
son and Alzheimer’s disease, and in other less common degenerative disorders, the clarification
of the connection between iron dysregulation and neurodegeneration may have an important
impact in understanding the basic mechanisms underlying neurodegenerative processes.
Overall, data presented in this paper suggest that this transgenic mouse model, expressing
the pathogenic mutant human ferritin light chain FTL498–499InsTC, can be used as a power-
ful tool to investigate the pathogenic mechanisms underlying neuroferritinopathy. Although
this is a first behavioral characterization, further studies on this mouse model might help eluci-
dating the mechanisms underlying the pathological phenotype and guide the development of
pharmacological tools to counteract it.
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